Iovance Biotherapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $59,952 | $49,324 | $73,694 | $58,554 |
Gross Profit | 3,288 | -417 | 28,151 | 18,731 |
EBITDA | -101,836 | -106,936 | -74,889 | -77,919 |
EBIT | -113,774 | -118,001 | -86,576 | -89,067 |
Net Income | -111,658 | -116,163 | -78,559 | -83,541 |
Net Change In Cash | 59,952 | 49,324 | 73,694 | 58,554 |
Free Cash Flow | -74,908 | -109,905 | -77,464 | -61,261 |
Cash | 132,469 | 171,668 | 115,694 | 164,186 |
Basic Shares | 334,511 | 322,868 | 304,890 | 303,269 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $164,070 | $1,189 | $238 | $0 |
Gross Profit | 40,075 | -9,566 | -21,135 | -13,980 |
EBITDA | -351,672 | -427,432 | -377,743 | -328,723 |
EBIT | -395,278 | -460,559 | -398,878 | -342,703 |
Net Income | -372,177 | -444,037 | -389,923 | -327,821 |
Net Change In Cash | 164,070 | 1,189 | 238 | 0 |
Cost of Revenue | 11,459 | |||
Free Cash Flow | -364,046 | -384,110 | -313,182 | -265,515 |
Cash | 115,694 | 114,888 | 231,731 | 78,229 |
Basic Shares | 289,877 | 235,131 | 159,259 | 153,406 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.33 |
2025-03-31 | -$0.36 |
2024-12-31 | -$0.26 |
